SALT LAKE CITY, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and INTERLINK Care Management, Inc.

Over 700,000 people in the U.S. died from heart disease in 2022, according to the Centers for Disease Control and Prevention.

The city of Milwaukee Health Department said "failure to act swiftly ... will place children at serious risk." ...

Farmers in Middle Georgia use free biosolids from the Macon Water Authority as fertilizer, but the EPA warns this practice ...

Redwire Corporation shows strong growth potential, despite dilution risks. Learn why RDW stock is rated Hold with speculative ...

Study results show that genetic sensitivity to stress was linked to a 49% higher risk of lung cancer in people of European ...

Microplastics were detected in almost every seafood sample found off the coast of the western U.S. in a recent study. The ...

Laura Hall of Selene explains how having a proper system of quality control can help a mortgage servicer better manage their ...

Experts say it is safe to eat fully cooked eggs to prevent the H5N1 virus or foodborne illnesses like salmonella. Here’s what ...

The latest announcement by Donald Trump that his so-called Sovereign Wealth Fund would be used to take over the real estate ...

Objective Glenohumeral (GH) osteoarthritis (OA) is the third most common large joint disease, after hip and knee OA. This ...